# US 12,006,358 B2 · Antibody against advanced glycation end products and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,006,358 B2
- Document ID: US12006358B2
- Status: Granted
- Kind: B2
- Application number: 17/271,381
- Filed: 2019-08-30
- Published: 2021-07-22
- Granted: 2024-06-11
- Earliest claimed: 2018-08-31
- Assignees: Bloom Technology, Inc.
- Applicants: Bloom Technology Corporation
- Inventors: Tetsuro Yamamoto; Shota Tsuchida; Tomoaki Shigeta; Kazumi Sasamoto; Mami Chirifu
- Web page: https://patentgrep.com/patent/US12006358B2

## CPC

- C07D 241/06: having one or two double bonds between ring members or between ring members and non-ring members
- C07K 16/18: against material from animals or humans
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 13/12: of the kidneys
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 15/08: for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 35/00: Antineoplastic agents
- C07D 241/12: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07K 16/44: against material not provided for elsewhere {, e.g. haptens, metals, DNA, RNA, amino acids}
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention is directed to providing a monoclonal antibody having high selectivity and affinity for AGEs, particularly, AGEs derived from glyceraldehyde or AGEs derived from glycolaldehyde, and an analysis method utilizing the same. Another object of the present invention is to provide methods for diagnosing, treating and preventing a disease using the monoclonal antibody.

## Claims

### Claim 1

A compound represented by formula (I) or (II):
wherein R1, R2, R3 and R4 are each independently selected from a hydrogen atom, a protecting group, and a peptide group having 1 to 1000 amino acid residues,
X1 and X2 represent —O— or —NH—;
Y1 and Y2 are a hydrogen atom, a protecting group, or a group:
R5 and R6 are each independently selected from a hydrogen atom, a protecting group, and a peptide group having 1 to 1000 amino acid residues;
or a cationic radical thereof, or a dication thereof or a salt thereof.

### Claim 2

A method for preparing an antibody, which comprises:
1) reacting lysine in which an amino group at α-position is protected and glyceraldehyde to obtain a reaction mixture;
2) fractionating the reaction mixture to obtain a fraction containing a compound represented by formula (Ia), (Ib), (IIa), or (IIb):
wherein R1, R3, and R6 are protecting groups
3) immunizing an animal using the fraction as an antigen to obtain an antibody.